Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension

Bibliography

• Kirson NY, Birnbaum HG, Ivanova JI, et al. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011;27(9):1763-8
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30(1):104-9
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert H, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30(20):2493-537
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the american college of cardiology foundation task force on expert consensus documents and the american heart association: developed in collaboration with the american college of chest physicians, american thoracic society, Inc., and the pulmonary hypertension association. Circulation 2009;119(16):2250-94
   PubMed Web of Science ®Google Scholar
• Tuder RM, Stacher E, Robinson J, et al. Pathology of pulmonary hypertension. Clin Chest Med 2013;34(4):639-50
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013;34(4):825-40
   PubMed Web of Science ®Google Scholar
• Channick R, Preston I, Klinger JR. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med 2013;34(4):811-24
   PubMed Web of Science ®Google Scholar
• Norman P. Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments. Exp Opin Orphan Drugs 2014;2(11):1137-45
   Web of Science ®Google Scholar
• Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64(3):583-620
   PubMed Web of Science ®Google Scholar
• Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev 2013;22(129):217-26
   PubMedGoogle Scholar
• Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11(3):554-9
   PubMed Web of Science ®Google Scholar
• Xing AP, Hu XY, Shi YW, et al. Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat. Inhal Toxicol 2012;24(8):468-75
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2010;43(6):629-34
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 2012;16(11):1055-63
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115(10):2811-21
   PubMed Web of Science ®Google Scholar
• Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005;115(10):2691-4
   PubMed Web of Science ®Google Scholar
• Berghausen E, ten Freyhaus H, Rosenkranz S. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. Handb Exp Pharmacol 2013;218:381-408
   PubMedGoogle Scholar
• Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Resp Crit Care Med 2008;178(1):81-8
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH). NCT01179737 2014. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01179737?sect=X30156#evnt
   Google Scholar
• Godinas L, Guignabert C, Seferian A, et al. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 2013;34(5):714-24
   PubMed Web of Science ®Google Scholar
• Novartis AG. Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators. WO132220; 2014
   Google Scholar
• Novartis AG; IRM LLC. Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension. WO030802; 2013
   Google Scholar
• IRM LLC. Compounds and compositions as c-kit kinase inhibitors. WO033070; 2013
   Google Scholar
• IRM LLC. Compounds and compositions as c-kit kinase inhibitors. WO033167; 2013
   Google Scholar
• IRM LLC. Compounds and compositions as c-kit kinase inhibitors. WO033203; 2013
   Google Scholar
• IRM LLC. Novartis pharmaceuticals UK Limited, compounds and compositions as pdgfr kinase inhibitors. WO033620; 2013
   Google Scholar
• Novartis AG. Novartis Pharma GmbH, Heterobicyclic Carboxamides As Inhibitors For Kinases. WO009487; 2008
   Google Scholar
• Lewis NL, Lewis LD, Eder JP, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009;27(31):5262-9
   PubMed Web of Science ®Google Scholar
• Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014;123(1):94-100
   PubMed Web of Science ®Google Scholar
• Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci USA 2014;111(14):5319-24
   PubMed Web of Science ®Google Scholar
• Roberts WG, Whalen PM, Soderstrom E, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 2005;65(3):957-66
   PubMed Web of Science ®Google Scholar
• Plé PA, Jung F, Ashton S, et al. Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett 2012;22(1):262-6
   PubMed Web of Science ®Google Scholar
• Medarametla V, Festin S, Sugarragchaa C, et al. PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension. Pulm Circ 2014;4(1):82-102
   PubMed Web of Science ®Google Scholar
• Zisman LS. Non-selective kinase inhibitors. WO110200; 2014
   Google Scholar
• Zisman LS. Therapeutic indications of kinase inhibitors. WO110198; 2014
   Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
   PubMed Web of Science ®Google Scholar
• Pandey A, Volkots DL, Seroogy JM, et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002;45:3772-93
   PubMed Web of Science ®Google Scholar